-
公开(公告)号：US20060275357A1
公开(公告)日：2006-12-07
申请号：US10552005
申请日：2004-04-06
申请人： Tomoyuki Oomura , Madhusudhan Pudipeddi , Colleen Ruegger , Alan Royce , Masaki Sasaki , Tokuhiro Tamura
发明人： Tomoyuki Oomura , Madhusudhan Pudipeddi , Colleen Ruegger , Alan Royce , Masaki Sasaki , Tokuhiro Tamura
IPC分类号： A61K31/138 , A61K9/48 , A61K9/20
CPC分类号： A61K31/145 , A61K9/0053 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/4858 , A61K9/4866 , A61K31/135 , A61K31/137 , A61K31/138 , A61K45/06 , A61K47/10 , A61K47/26 , A61K2300/00
摘要： A solid pharmaceutical composition suitable for oral administration, comprising: (a) S1P receptor agonist; and (b) a sugar alcohol.
摘要翻译： 适用于口服给药的固体药物组合物，其包含：（a）S1P受体激动剂; 和（b）糖醇。
-
公开(公告)号：US20080064760A1
公开(公告)日：2008-03-13
申请号：US11575203
申请日：2005-10-27
申请人： Ping Li , Madhusudhan Pudipeddi , Alan Royce , Sara Hynes , Abu Serajuddin , Michael Ambuhl , Barbara Luckel
发明人： Ping Li , Madhusudhan Pudipeddi , Alan Royce , Sara Hynes , Abu Serajuddin , Michael Ambuhl , Barbara Luckel
IPC分类号： A61K47/00
CPC分类号： A61K31/27 , A61K9/1075 , A61K9/4858 , A61K38/13
摘要： A spontaneously dispersible pharmaceutical composition comprising a poorly soluble drug and a carrier medium comprising (1) a lipophilic component, (2) a surfactant, and optionally (3) a hydrophilic component, wherein at least one of the components (1) to (3) is solid at room temperature. A particularly useful hydrophilic component in the system is a polymer that is solid at room temperature, e.g., solid PEG.
摘要翻译： 一种包含难溶性药物和载体介质的可自发分散的药物组合物，其包含（1）亲脂性组分，（2）表面活性剂和任选的（3）亲水组分，其中至少一种组分（1）至（3） ）在室温下是固体。 系统中特别有用的亲水组分是在室温下为固体的聚合物，例如固体PEG。
-
公开(公告)号：US20070134319A1
公开(公告)日：2007-06-14
申请号：US10583646
申请日：2004-12-22
CPC分类号： A61K9/1075 , A61K9/4858 , A61K31/66 , A61K31/663 , A61K47/14
摘要： A pharmaceutical formulation comprising an oral dosage form containing a bisphosphonic acid or a salt thereof and an inactive ingredient selected from: an ester of a medium chain fatty acid, or a lipophilic polyethylene glycol ester, said inactive ingredient having a hydrophilic lipophilic balance (HLB) of from about 1 to about 30.
摘要翻译： 一种药物制剂，其包含含有双膦酸或其盐的口服剂型和选自：中链脂肪酸或亲脂性聚乙二醇酯的无活性成分，所述非活性成分具有亲水亲油平衡（HLB） 为约1至约30。
-
公开(公告)号：US5331942A
公开(公告)日：1994-07-26
申请号：US930067
申请日：1992-08-14
申请人： Ross McDonald , Alan Royce , James C. Stephen
发明人： Ross McDonald , Alan Royce , James C. Stephen
CPC分类号： A47J37/0694 , A47J37/0786
摘要： A fuel support grill rack (10) for use in a barbecue grill (11) is disclosed. The grill rack (10) is positioned below a cooking grid. The grill rack (10) includes a substantially horizontal first surface (20) for supporting charcoal and a second surface (21) comprised of a pair of troughs (30a,30b) formed by at least two trough walls (31) angularly depending downwardly from the first surface (20). Each trough (30a,30b) further includes a first end trough (32), a second end trough (33), and an inner trough (34) disposed therebetween. The inner trough (34) is deeper and extends below the first and second end troughs (32, 33). The apices (35, 36) of the first end trough and the second end trough are positioned above an apex (37) of the inner trough (34).
摘要翻译： 公开了一种用于烧烤架（11）中的燃料支架格架（10）。 烤架（10）位于烹饪电网的下方。 格栅架（10）包括用于支撑木炭的基本上水平的第一表面（20）和由一对槽（30a，30b）组成的第二表面（21），所述第二表面由至少两个槽壁（31）形成，所述至少两个槽壁 第一表面（20）。 每个槽（30a，30b）还包括第一端槽（32），第二端槽（33）和设置在它们之间的内槽（34）。 内槽（34）更深并在第一和第二端槽（32,33）的下方延伸。 第一端槽和第二端槽的顶点（35,36）位于内槽（34）的顶点（37）的上方。
-
5.发明申请System for predicting reduction in concentration of a target material in a flow of fluid 有权用于预测流体中目标材料的浓度降低的系统公开(公告)号：US20050218082A1
公开(公告)日：2005-10-06
申请号：US11076426
申请日：2005-03-10
申请人： Christian Williamson , Alan Royce , Mihaela Stefan
发明人： Christian Williamson , Alan Royce , Mihaela Stefan
CPC分类号： C02F1/008 , A61L9/205 , C02F1/32 , C02F1/722 , C02F2101/32 , C02F2101/34 , C02F2101/36 , C02F2101/38 , C02F2103/06 , C02F2201/3227 , C02F2201/326 , C02F2209/001 , C02F2209/003 , C02F2209/04 , C02F2209/05 , C02F2209/06 , C02F2209/08 , C02F2209/10 , C02F2209/20 , C02F2209/23 , C02F2209/40 , C02F2303/04 , C02F2305/023 , C02F2305/10 , Y02W10/37
摘要： An ultraviolet fluid treatment system having feedback control using a kinetic model and a reactor model that interact with one another. The kinetic model uses readily measured fluid properties upstream and downstream of a radiation zone to calculate the conversion of a target contaminant as it passes through the fluid treatment system. This obviates the need to measure the contaminant concentration directly, which generally is too slow to permit real-time control. A reactor model relates system operating cost to system operating parameters, such as electrical power consumption and/or rate of oxidant addition, where applicable. The reactor model is linked to the kinetic model and is used to optimize operating cost by adjusting system operating parameters based on a comparison between the conversion obtained from the kinetic model and the overall treatment objectives. A control center, an ultraviolet fluid treatment apparatus, and a method of treating a fluid are also disclosed.
摘要翻译： 具有使用动力学模型和相互作用的反应器模型的反馈控制的紫外线流体处理系统。 动力学模型使用辐射区上游和下游的容易测量的流体特性来计算目标污染物通过流体处理系统时的转化率。 这避免了直接测量污染物浓度的需要，这通常太慢，无法实时控制。 反应器模型将系统运行成本与系统运行参数（如适用的电力消耗和/或氧化剂添加速率）相关联。 反应器模型与动力学模型相关联，并且用于通过基于从动力学模型获得的转化与总体处理目标之间的比较来调整系统操作参数来优化操作成本。 还公开了一种控制中心，紫外线流体处理装置和处理流体的方法。
-
公开(公告)号：USD346531S
公开(公告)日：1994-05-03
申请号：US930222
申请日：1992-08-14
申请人： James C. Stephen , Ross McDonald , Alan Royce
设计人： James C. Stephen , Ross McDonald , Alan Royce
-
7.发明授权System for predicting reduction in concentration of a target material in a flow of fluid 有权用于预测流体中目标材料的浓度降低的系统公开(公告)号：US07531095B2
公开(公告)日：2009-05-12
申请号：US11076426
申请日：2005-03-10
CPC分类号： C02F1/008 , A61L9/205 , C02F1/32 , C02F1/722 , C02F2101/32 , C02F2101/34 , C02F2101/36 , C02F2101/38 , C02F2103/06 , C02F2201/3227 , C02F2201/326 , C02F2209/001 , C02F2209/003 , C02F2209/04 , C02F2209/05 , C02F2209/06 , C02F2209/08 , C02F2209/10 , C02F2209/20 , C02F2209/23 , C02F2209/40 , C02F2303/04 , C02F2305/023 , C02F2305/10 , Y02W10/37
摘要： An ultraviolet fluid treatment system having feedback control using a kinetic model and a reactor model that interact with one another. The kinetic model uses readily measured fluid properties upstream and downstream of a radiation zone to calculate the conversion of a target contaminant as it passes through the fluid treatment system. This obviates the need to measure the contaminant concentration directly, which generally is too slow to permit real-time control. A reactor model relates system operating cost to system operating parameters, such as electrical power consumption and/or rate of oxidant addition, where applicable. The reactor model is linked to the kinetic model and is used to optimize operating cost by adjusting system operating parameters based on a comparison between the conversion obtained from the kinetic model and the overall treatment objectives. A control center, an ultraviolet fluid treatment apparatus, and a method of treating a fluid are also disclosed.
摘要翻译： 具有使用动力学模型和相互作用的反应器模型的反馈控制的紫外线流体处理系统。 动力学模型使用辐射区上游和下游的容易测量的流体特性来计算目标污染物通过流体处理系统时的转化率。 这避免了直接测量污染物浓度的需要，这通常太慢，无法实时控制。 反应器模型将系统运行成本与系统运行参数（如适用的电力消耗和/或氧化剂添加速率）相关联。 反应器模型与动力学模型相关联，并且用于通过基于从动力学模型获得的转化与总体处理目标之间的比较来调整系统操作参数来优化操作成本。 还公开了一种控制中心，紫外线流体处理装置和处理流体的方法。
-
8.发明申请Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form 审中-公开口服给药药物组合物，其包含微粉化形式的递送剂公开(公告)号：US20070065505A1
公开(公告)日：2007-03-22
申请号：US10564259
申请日：2004-07-09
申请人： Shoufeng Li , Anasuya Ghosh , Simon Bateman , Moise Azria , Alan Royce
发明人： Shoufeng Li , Anasuya Ghosh , Simon Bateman , Moise Azria , Alan Royce
CPC分类号： A61K47/18 , A61K9/1617 , A61K9/2013 , A61K38/23 , A61K47/183
摘要： Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.
摘要翻译： 固体药物组合物及其用途的方法适用于药物活性剂的口服递送，例如， 肽，包含治疗有效量的药理活性剂; 交聚维酮或聚维酮; 并公开了所述药理活性剂的递送剂。 组合物使用微粒化形式的递送剂，其提供药理活性剂，特别是降钙素的增强的生物利用度。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.031 秒)
